A mesenchymal glioma stem cell profile is related to clinical outcome

Oncogenesis

Volumn 3, Issue 3, 2014, Pages

  Balbous, A ^a,b,c   Cortes, U ^a,b,c   Guilloteau, K ^a,b,c   Villalva, C ^a,b,c   Flamant, S ^d,e   Gaillard, A ^a,b   Milin, S ^c   Wager, M ^c   Sorel, N ^a,b,c   Guilhot, J ^a   Bennaceur Griscelli, A ^d,e   Turhan, A ^d,e   Chomel, J C ^a,b,c   Karayan Tapon, L ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d Centre National de la Recherche Scientifique   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

COL1A1; glioblastoma stem cells; IFITM1; mesenchymal profile; survival

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYONIC STEM CELL; GENE EXPRESSION; GLIOMA; IN VITRO STUDY; MESENCHYMAL GLIOMA STEM CELL; MESENCHYMAL STEM CELL; NEURAL STEM CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84927668332     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.5     Document Type: Article

References (54)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352: 987-996.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
3. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
4. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA et al. Identification of A2B5\+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-514, discussion 514-515.
5. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
6. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(\+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
7. Wang J, Sakariassen P∅, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer J Int Cancer 2008; 122: 761 768.
8. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-452.
9. Joo KM, Kim SY, Jin X, Song SY, Kong D-S, Lee J-I et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Investig J Tech Methods Pathol 2008; 88: 808-815.
10. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133\+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
11. Kang M-K, Kang S-K. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007; 16: 837-847.
12. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
13. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res 2013; 319: 2230-2243.
14. Denysenko T, Gennero L, Roos MA, Melcarne A, Juenemann C, Faccani G et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct 2010; 28: 343-351.
15. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013; 110: 8644-8649.
16. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
17. Wei CL, Miura T, Robson P, Lim S-K, Xu X-Q, MY-C Lee et al. Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells Dayt Ohio 2005; 23: 166-185.
18. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2: 333-344.
19. Odom DT, Dowell RD, Jacobsen ES, Gordon W, Danford TW, MacIsaac KD et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genet 2007; 39: 730-732.
20. Assou S, Le Carrour T, Tondeur S, Ström S, Gabelle A, Marty S et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells Dayt Ohio 2007; 25: 961-973.
21. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124: 1111-1115.
22. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
23. Kang J, Shakya A, Tantin D. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem Sci 2009; 34: 491-499.
24. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162.
25. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
26. Mü ller F-J, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008; 455: 401-405.
27. Holmberg J, He X, Peredo I, Orrego A, Hesselager G, Ericsson C et al. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One 2011; 6: e18454.
28. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
29. Choi HW, Kim JS, Choi S, Jang HJ, Kim MJ, Choi Y et al. Neural stem cells achieve and maintain pluripotency without feeder cells. PLoS One 2011; 6: e21367.
30. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 2002; 12: 432-438.
31. Akiyama Y, Hosoya T, Poole AM, Hotta Y. The gcm-motif: a novel DNA-binding motif conserved in Drosophila and mammals. Proc Natl Acad Sci USA 1996; 93: 14912-14916.
32. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009; 1: a003129.
33. Sajithlal GB, McGuire TF, Lu J, Beer-Stolz D, Prochownik EV. Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer J Int Cancer 2010; 127: 2268-2278.
34. Dong J, Zhao Y, Huang Q, Fei X, Diao Y, Shen Y et al. Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev 2011; 7: 141-152.
35. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helén PT, Schraml P et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000; 60: 6617-6622.
36. Kim Y-W, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J et al. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro-Oncol 2013; 15: 829-839.
37. Mori-Akiyama Y, Akiyama H, Rowitch DH, de Crombrugghe B. Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc Natl Acad Sci USA 2003; 100: 9360-9365.
38. Liu Y, Carson-Walter EB, Cooper A, Winans BN, Johnson MD, Walter KA. Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol 2010; 99: 13-24.
39. Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PPL. IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell 2005; 9: 745-756.
40. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007; 26: 594-603.
41. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006; 66: 1949-1955.
42. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14: 6097-6105.
43. Yu F, Ng SSM, Chow BKC, Sze J, Lu G, Poon WS et al. Knockdown of interferoninduced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol 2011; 103: 187-195.
44. Parsons DW, Jones S, Zhang X, JC-H Lin, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
45. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352: 997-1003.
46. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
47. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
48. Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett 2013; 331: 131-138.
49. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225, discussion 226-229.
50. Villalva C, Martin-Lannereé S, Cortes U, Dkhissi F, Wager M, Le Corf A et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer J Int Cancer 2011; 128: 826-838.
51. Villalva C, Cortes U, Wager M, Tourani J-M, Rivet P, Marquant C et al. O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci 2012; 13: 6983-6994.
52. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G et al. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007; 25: 803-816.
53. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
54. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res Off J Am Assoc Cancer Res 2009; 15: 6541-6550.